Differences

This shows you the differences between two versions of the page.

--- pdl1nsclcatezosp263.docx [2026/04/08 03:50] – created gilbert
+++ pdl1nsclcatezosp263.docx [2026/04/08 03:52] (current) – gilbert
@@ Line 9: / Line 9: @@
 **D**iagnostic test: PDL1 SP263
-**Result:       Positive TPS >= 50% or Negative TPS < 50% or Inadequate**
+**Result:       Positive TPS >= 50% <color red> **OR** </color> Negative TPS < 50% <color red> **OR** </color> Inadequate**
 Performed on block %%**%%*
@@ Line 17: / Line 17: @@
 Batch controls: **Adequate**; On slide controls: **Adequate**; Immune cell staining: **Present**;
-Disclaimer: Atezolizumab monotherapy adjuvant for resected stage II to stage IIIA NSCLC who received platinum-based chemotherapy and whose tumours have PD_L1 expression on ≥ 50% of tumour cells and do not have EGFR or ALK mutations. (Reference: Enriqueta Felip, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage II–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial, The Lancet, Volume 398, Issue 10308, 2021, Pages 1344-1357,ISSN 0140-6736. VENTANA PD-L1 (SP263) Assay is intended for the qualitative detection of the programmed death ligand 1 (PD-L1) protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tissue stained with OptiView DAB IHC Detection Kit on a BenchMark IHC/ISH instrument.This assay is not interchangeable with other PD-L1 assays and cannot be used for other type of cancers. On slide controls include one piece of tonsil (with expected PD-L1 staining positive in immune cells and keratinocytes) and one piece of liver (with expected PD-L1 staining negative in hepatocytes).
+Disclaimer: Atezolizumab monotherapy adjuvant for resected stage II to stage IIIA NSCLC who received platinum-based chemotherapy and whose tumours have PD_L1 expression on ≥ 50% of tumour cells and do not have EGFR or ALK mutations. (Reference: Enriqueta Felip, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage II–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial, The Lancet, Volume 398, Issue 10308, 2021, Pages 1344-1357,ISSN 0140-6736. VENTANA PD-L1 (SP263) Assay is intended for the qualitative detection of the programmed death ligand 1 (PD-L1) protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tissue stained with %%OptiView%% DAB IHC Detection Kit on a %%BenchMark%% IHC/ISH instrument.This assay is not interchangeable with other PD-L1 assays and cannot be used for other type of cancers. On slide controls include one piece of tonsil (with expected PD-L1 staining positive in immune cells and keratinocytes) and one piece of liver (with expected PD-L1 staining negative in hepatocytes).
 Test ID: PDL1NSCLCATEZOSP263
 {{:PDL1NSCLCATEZOSP263.docx | PDL1NSCLCATEZOSP263}}